Happiness and Multiple Sclerosis
Tandem bike a great equalizer for cyclists with different fitness levels
Phase IV Tysabri data #MS Research # MSBlog Effect of Tysabri
Mitoxantrone Study: Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in WorseningMultiple Sclerosis) study.
Patient taking Novartis MS pill developed rare disease
Could Sleep Deprivation Aggravate Multiple Sclerosis?
ABC News
Sleep Doubles Growth Of Brain Repair Cells. This explains why multiple sclerosis, an autoimmune disease that destroys myelin and kills oligodendrocytes, is so devastating. Hardened scars in the brain are the classic feature in the more than two million victims of the disease. Scientists at the University of Wisconsin-Madison (UoW) have discovered another reason why sleep is great! Resting boosts the growth of special cells — called oligodendrocytes — that repair the brain when it is injured, according to new findings reported in the Journal of Neuroscience.
High risk of cardiovascular diseases after diagnosis of multiple sclerosis We recommend careful surveillance and preventive CVDs measures among MS patients, particularly among the women.
CAMPATH (Alemtuzumab) improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis
Alemtuzumab was associated with a greater chance of improved contrast sensitivity in patients with RRMS and may delay the worsening of visual function.
The impact of sexual dysfunction on health-related quality of life in people with multiple sclerosis
Sexual dysfunction is a prevalent symptom in multiple sclerosis (MS) that may affect patients’ health-related quality of life (HrQoL). In patients with MS, sexual dysfunction has a much larger detrimental impact on the mental health aspects of HrQoL than severity of physical disability. The study population included 6183 persons (mean age: 50.6, SD = 9.6; 74.7% female, 42.3% currently employed. Participants were recruited from a large MS registry, the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry.
Migraine sufferers prone to poor blood flow
Migraines Linked to Structure of Brain Arteries
Longitudinal Change in Physical Activity & Its Correlates in Relapsing-Remitting Multiple Sclerosis
Retinal periphlebitis is associated with multiple sclerosis severity
Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab (TYSABRI)
Protein kinase C polymorphisms and vitamin D levels in multiple sclerosis
Labor induction and augmentation in women with multiple sclerosis
CLICK ON "READ MORE" BELOW FOR 538 MORE STUDIES & ARTICLES WE POSTED IN SEPTEMBER
Are there Epstein-Barr virus seronegative patients with multiple sclerosis?
Renal deterioration in multiple sclerosis patients with neurovesical dysfunction
Relating health-related Quality of Life to disability progression in multiple sclerosis, using the 5-level EQ-5D
Natalizumab-induced autoimmune hepatitis in a patient with multiple sclerosis
CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions
MRI characteristics of familial and sporadic multiple sclerosis patients
Rare MEFV variants are not associated with risk to develop multiple sclerosis and severity of disease
Common genetic variants in the plasminogen activation pathway are not associated with multiple sclerosis
Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis
Studies in Experimental Autoimmune Encephalomyelitis Do Not Support Developmental Bisphenol A Exposure as an Environmental Factor in Increasing Multiple Sclerosis Risk
Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia
Natalizumab inhibits the expression of human endogenous retroviruses of the W family in multiple sclerosis patients: a longitudinal cohort study
Research and Markets: Relapsing Remitting Multiple Sclerosis ...
Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis
Sun
exposure may have direct effects on MRI measures of neurodegeneration
in MS, independently of vitamin D. Multivitamin supplementation summer,
sun exposure and darker eye color had the strongest associations with
vitamin D metabolite levels in the MS group. Increased summer sun
exposure was associated with increased grey matter volume and whole
brain volume after correcting for Extended Disability Status Scale in
the MS group. Inclusion of 25-hydroxy vitamin D3 levels did not
substantially affect the positive associations of sun exposure with WBV
and GMV...
Primary progressive multiple sclerosis: progress and challenges
Primary progressive multiple sclerosis (MS) has long been recognised as presenting great difficulties to our management of what is increasingly a treatable neurological disease...
The interface between neurology and psychiatry: the case of multiple sclerosis
There has been a surge in interest in the boundaries of psychiatry, both as a specialty in its own right and as a branch of medicine separate from neurology....
Sun
exposure may have direct effects on MRI measures of neurodegeneration
in MS, independently of vitamin D. Multivitamin supplementation summer,
sun exposure and darker eye color had the strongest associations with
vitamin D metabolite levels in the MS group. Increased summer sun
exposure was associated with increased grey matter volume and whole
brain volume after correcting for Extended Disability Status Scale in
the MS group. Inclusion of 25-hydroxy vitamin D3 levels did not
substantially affect the positive associations of sun exposure with WBV
and GMV...Primary progressive multiple sclerosis: progress and challenges
Primary progressive multiple sclerosis (MS) has long been recognised as presenting great difficulties to our management of what is increasingly a treatable neurological disease...
The interface between neurology and psychiatry: the case of multiple sclerosis
There has been a surge in interest in the boundaries of psychiatry, both as a specialty in its own right and as a branch of medicine separate from neurology....
Cocoa, neurovascular coupling, and neurodegeneration: The good, the bad, and the ugly
Neurology September 3, 2013 81:863-864; published ahead of print August 7, 2013
Though the human brain is only ∼2% of body mass, it represents more than 20% of total body oxygen and energy consumption,1,2 and the supply of blood to the active neurons must match their metabolic demand. Fortunately, the tight coupling between capillary endothelial cells, astrocytes, pericytes, and neurons—dubbed the neurovascular unit—ensures precise modulation of regional blood flow in response to local metabolic demand. This integration of
supply and demand, termed neurovascular coupling (NVC), is critical to neurophysiologic health. Indeed, accumulating evidence shows an important role for cerebral vascular insufficiency in neurodegenerative diseases ranging from vascular cognitive impairment3 to Alzheimer disease.4 Therefore, targeting cerebral vascular pathology is a promising option for primary and secondary prevention of neurodegenerative diseases and subsequent cognitive impairments.
Evaluation of plaque detection and optimum time of enhancement in acute attack multiple sclerosis after contrast injection. Acta Radiology 2013 Aug.
PURPOSE: To find the best time to detect MS plaques on MRI after Gadobutrol injection.
CONCLUSION: The maximum number of enhancing plaques in MS patients was detected 15 min after contrast agent administration and the size and signal intensity of the lesions also increased remarkably at this time. READ MORE
Do any of your relatives have MS?
There have been a couple of mentions of a "slight" genetic link for multiple sclerosis, such as the subject of this older blog: Is Multiple Sclerosis Genetic?
\
CDC Details Use of Sleep Meds
Some 4% of American adults used prescription sleep medications in the past month, government survey data showed, with the highest rates among women, the elderly, whites, and the college-educated.
VIDEO: Software developer reveals challenges of living with multiple sclerosis
Alistair Farrugia walks out of the lift, leaning on the wheeled walker his company bought to assist his mobility at its offices. The young software developer ...
Of Mice and Men: Problems with Animal Studies Highlighted in a New Light
John Ioannidis of Stanford and colleagues published an important paper in PLoS Biology, “Evaluation of Excess Significance Bias in Animal Studies of Neurological Diseases.”
Area man to bike 200 miles in multiple sclerosis fundraiser
Norman Eubank hadn't ridden a bicycle in 34 years when he decided he wanted to do a sprint triathlon. "I had turned 50, and I guess I needed to prove to myself ...»
Blair Underwood Makes Mom Proud
Actor Blair Underwood's mother was thrilled when he signed up to play disabled detective Ironside on Tv because she has been confined to a wheelchair with Multiple Sclerosis
Alzheimers, ALS and Multiple Sclerosis
Once I was diagnosed with multiple sclerosis, I became acutely aware of other chronic diseases, especially Alzheimer's disease and ALS (amyotrophic lateral ...
European Approval for Aubagio (Teriflunomide) in MS
Results of the TEriflunomide Multiple Sclerosis (TEMSO) trial, published in the New England Journal of Medicine in 2011, showed a significant reduction in ...
Cool cars cruise for cause
A&W Cruisin' for A Cause held a fundraiser last week in Maple Ridge for the Multiple Sclerosis Society of Canada. A&W restaurants in B.C. and the Yukon raised ...
Eleven-year-old completes run
For the past week, Tyler has been an 11-year-old fund- and awareness-raising machine for multiple sclerosis as he ran tip-to-tip across the Island along the ...
TYSABRI: The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated Relapsing Multiple Sclerosis.
Risk factors for rare diseases can be risky to define: PML and Tysabri (natalizumab)
Neurology September 3, 2013 81:858-859
When rare neurologic diseases become topics of editorials in journals such as Nature Neuroscience,1 the New England Journal of Medicine,2 and Neurology®,3 there is usually something more of general interest than the rare disease itself. Such is the case for progressive multifocal leukoencephalopathy (PML), the JC virus–induced demyelinating disease that was once relegated for discussion to the back of the textbook, whether in microbiology or neurology. Not any longer. Incidence and publication of cases of PML have risen more than 50-fold within the last decade.
AUBAGIO (Teriflunomide) in relapsing multiple sclerosis: therapeutic utility.
Teriflunomide is an oral, once-daily disease-modifying therapy (DMT) approved in the USA, Australia, and Argentina for the treatment of relapsing forms of multiple sclerosis (RMS). Teriflunomide reversibly limits the expansion of activated T and B cells associated with the inflammatory process purportedly involved in multiple sclerosis pathogenesis, while preserving lymphocytes for routine immune surveillance. In an extensive clinical development program, teriflunomide demonstrated consistent benefits on both clinical and magnetic resonance imaging outcomes. In long-term studies, teriflunomide treatment was associated with low rates of relapse and disability progression for up to 8 years. The safety profile of teriflunomide has been well characterized, with adverse events generally mild to moderate in nature and infrequently leading to permanent treatment discontinuation. The evidence reviewed here indicates that teriflunomide is an effective addition to the current DMTs used to treat RMS....
Laquinimod for multiple sclerosis.
We found low-level evidence for the use of laquinimod as a disease-modifying therapy for MS because only one study with limited quality (high risk of attrition bias) was included. The published study suggests that laquinimod at a dose of 0.6 mg orally administered once daily may be safe and have potential benefits for most patients with RRMS in the short term. We are waiting for the publication of ongoing trials....
Therapeutic Decisions in Multiple Sclerosis-Moving Beyond Efficacy
In this article, we focus primarily on the safety of DMTs in the context of understanding their pharmacological characteristics, including molecular targets, mechanism of action, chemical structure, and metabolism. Recognizing the individual classes of DMTs described here may be valuable when considering use of such agents sequentially or possibly in combination....
L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients
Objective: To find biomarkers identifying patients at risk for the development of progressive multifocal leukoencephalopathy (PML) during natalizumab treatment.
Conclusions: The cell-based assessment of the percentage of L-selectin-expressing CD4 T cells could provide an urgently needed biomarker for individual PML risk assessment....
Mesenchymal Stem Cells (MSC) derived from mice with Experimental Autoimmune Encephalomyelitis (EAE) suppress EAE and have similar biological properties with MSC from healthy donors.
A Long-Term Follow-Up Study Using IPMSSG Criteria in Children With CNS Demyelination.
Comparison of BLADE and conventional T2-TSE sequences for the sagittal visualization of the cervical spinal cord in multiple sclerosis patients - A case report.
Inhibition of Endogenous Activated Protein C Attenuates Experimental Autoimmune Encephalomyelitis by Inducing Myeloid-Derived Suppressor Cells.
Autoantigens and Autoantibodies in Multiple Sclerosis.
Gene expression changes underlying cortical pathology: clues to understanding neurological disability in multiple sclerosis.
Chromosomal radiosensitivity in patients with multiple sclerosis.
Magnetic resonance monitoring of lesion evolution in multiple sclerosis.
Targeting ion channels for the treatment of autoimmune neuroinflammation.
Assessing humoral immunocompetence after alemtuzumab treatment in MS
Immune competence after alemtuzumab treatment of multiple sclerosis
Neurology September 3, 2013 81:872-876; published ahead of print August 7, 2013
Retinal periphlebitis is associated with multiple sclerosis severity
Neurology September 3, 2013 81:877-881; published ahead of print July 31,2013
Application and a proposed modification of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Canadian cohort of patients with clinically isolated syndromes
The 2005 and 2010 McDonald criteria utilize magnetic resonance imaging (MRI) to provide evidence of disease dissemination in space (DIS) and time (DIT) for the diagnosis of multiple sclerosis (MS) in patients who have clinically isolated syndromes (CIS). Using 2010 McDonald criteria, 30% of the CIS patients could be diagnosed with MS using a single MRI scan. Inclusion of symptomatic lesions in the DIT criteria further increases this proportion to 33%...
Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis
The objective of this paper is to investigate four-year outcomes of interferon beta (IFNB)-treated patients with multiple sclerosis (MS) according to their clinical or magnetic resonance imaging (MRI) activity status at first year of treatment. The four-year outcomes of patients with isolated MRI activity did not differ from those fulfilling EMA criteria at first year of IFNB treatment...
Cytomegalovirus seropositivity is negatively associated with multiple sclerosis
Epidemiological data suggest a role for common viruses in the pathogenesis of multiple sclerosis (MS), and recent data showed a negative association of past cytomegalovirus (CMV) infection on pediatric MS risk. CMV is negatively associated with adult-onset MS pathology, consistent with results from a study on pediatric MS cases. It remains to be shown whether this negative association is due to a true protective effect of CMV infection on MS risk.
Retinal periphlebitis is associated with multiple sclerosis severity
To assess the association of primary retinal inflammation, namely retinal periphlebitis (RP) and microcystic macular edema, with clinical, brain, and retinal imaging biomarkers of multiple sclerosis (MS) severity. These results support the role of RP as a biomarker of MS severity.
Immune competence after alemtuzumab treatment of multiple sclerosis
To determine the immunocompetency of patients with multiple sclerosis treated with the lymphodepleting humanized monoclonal antibody alemtuzumab. In this small historically controlled pilot study, we demonstrated i) retained humoral immunologic memory (in the form of antibodies against common viruses and response to recall antigens), and ii) the retained ability to mount a humoral immune response against a novel antigen after treatment with alemtuzumab.
A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis
To evaluate the effectiveness and cost-effectiveness of a six-session group-based program for managing MS-fatigue (Fatigue: Applying Cognitive behavioural and Energy effectiveness Techniques to lifeStyle (FACETS)). FACETS is effective in reducing fatigue severity and increasing fatigue self-efficacy. However, it is difficult to assess the additional cost in terms of cost-effectiveness (ie, cost per QALY) as improvements in fatigue are not reflected in the QALY outcomes, with no significant differences between FACETS and CLP. The strengths of this trial are its pragmatic nature and high external validity.
Brain atrophy and lesion load predict long term disability in multiple sclerosis
To determine whether brain atrophy and lesion volumes predict subsequent 10 year clinical evolution in multiple sclerosis (MS). This large multicentre study points to the complementary predictive value of atrophy and lesion volumes for predicting long term disability in MS.
Chronic Headache: Is a CAM Therapy Worth a Try?
Trophos Completes Patient Enrolment in a First Study of Olesoxime in Relapsing Remitting Multiple Sclerosis
Living with MS can be Hell
There’s never been a more deserving time to treat yourself to your favourite Hell pizza. The irreverent company’s 25 Auckland outlets are throwing their support behind Multiple Sclerosis Auckland’s annual Street Appeal, donating $1 for every double-size pizza and 50 cents for every snack pizza sold from 6-12 September.
Novartis' MS Drug Gilenya Under FDA Investigation for PML Case
FDA has issued a safety alert after a patient with multiple sclerosis (MS) in Europe developed a rare and serious brain infection known as progressive multifocal leukoencephalopathy (PML) following treatment with Gilenya (fingolimod).
If Amy Winehouse was here, she'd be jumping out the plane too
Janis Winehouse's fierce fight with multiple sclerosis means she struggles to walk — but she reckons Amy would be doing the charity parachute jump beside her if she were alive! Janis, 58, will perform a parachute jump on September 29 to raise money for the Amy Winehouse Foundation and create awareness about multiple sclerosis (MS), which she suffers from.
MS and Elevated Liver Enzymes: A Genetic Connection?
Healthline
Elevated liver enzymes are a regrettably common complication of multiple sclerosis and its treatments. A new study at the University of British Columbia (UBC) is ...
No Consensus on Crowded MS Drug field
Pharmacy Practice News
“This is an oversimplified recommendation that we strongly feel needs to be more nuanced,” argued representatives of the AAN's Multiple Sclerosis Working ...
Sunshine and multiple sclerosis
Are Your Personal Assets at Risk if You're Sued?
“Amazing Race” host Phil Keoghan leads the cyclists of the No
Opportunity Wasted team which advocates for multiple sclerosis research.
More than 2,000 Puget Sound cyclists will be joining Keoghan in the
Washington Bike MS Ride Sept. 7-8 in Skagit and Island counties.
Disabled Sartell man finds chair that he thought was stolen Mark Demars has multiple sclerosis, and thought a new office chair he
had delivered to his apartment was taken by thieves. He lives at Hope
Village, an apartment complex that caters to people with disabilities.
The association between cerebral venous thrombosis (CVT) and multiple sclerosis (MS) has already been reported in patients with clinically definite MS in relation to intravenous methylprednisolone (IVMP) or previously performed lumbar puncture (LP).
The impact of sexual dysfunction on health-related quality of life in people with multiple sclerosis.
Participants were recruited from a large MS registry, the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry. Participants self-reported demographic information and completed the Patient Determined Disease Steps (PDDS), MSISQ-19, and the Short Form-12 (SF-12).
In patients with MS, sexual dysfunction has a much larger detrimental impact on the mental health aspects of HrQoL than severity of physical disability.
Need for differentiation of real and clinical important change in research on responsiveness of walking outcome measures in multiple sclerosis.
Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis.
The objective of this paper is to investigate four-year outcomes of interferon beta (IFNB)-treated patients with multiple sclerosis (MS) according to their clinical or magnetic resonance imaging (MRI) activity status at first year of treatment. The four-year outcomes of patients with isolated MRI activity did not differ from those fulfilling EMA criteria at first year of IFNB treatment.
Genzyme's Aubagio approved by European Commission for Multiple Sclerosis treatment
Sep 02, 2013 (Menafn - M2 EQUITYBITES via COMTEX) --Genzyme, a division of Sanofi SNY, announced on Friday the grant of marketing authorisation by the European Commission for Aubagio (teriflunomide) 14 mg, a once-daily, oral therapy indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS)
Treating Rare Neurologic Diseases
Although neurologists are frequently faced with the management of rare diseases, there is little generic guidance for the approach to management. There are complexities with respect to diagnosis, counselling, treatment and monitoring which are idiosyncratic to rare diseases. Here we use a case report as the basis for discussion of the management of rare neurological diseases. We discuss current issues, guidance from regulatory bodies, and offer practical tips for diagnosis, treatment and monitoring, including the use of decision tree analysis. We offer a generic algorithm to aid neurologists when facing rare conditions.
Jack Osbourne 'Dancing With the Stars' to Shine Light on Multiple ...
ABC News
Just over a year ago, Jack Osbourne was a new father finding out he had multiple sclerosis. "The Osbournes" star was admittedly angry and frustrated. Now ...
Apitope releases positive results from Phase I clinical study of ...
Pharmaceutical Business Review
When patients with relapsing multiple sclerosis were treated with intradermal injection of ATX-MS-1467, the MRI results showed a decrease in the number of ...
First study to investigate the human genome in multiple sclerosis
EurekAlert (press release)
The National Institutes of Health (NIH) awarded Benaroya Research Institute at Virginia Mason (BRI) a $1.9 million grant to find marks in the human genome ...
The invisible side of MS and preview On-Line Training for Caregivers, Social ...
Glendale eatery fundraiser to benefit those with MS
Arizona Republic
The fundraiser, which benefits the National Multiple Sclerosis Society, was created to honor Denise Anderson, who is the mother of one of The Shout House's ...
Business RadioX®'s Eugeria! Radio™ Addresses the Invisible Side of Multiple Sclerosis
FDA Alert for Multiple Sclerosis Drug
The Food and Drug Administration has issued an alert concerning the multiple sclerosis drug fingolimod, after a patient in Europe developed a rare and serious brain infection while taking the medication. Fingolimod is sold under the brand name Gilenya by Novartis (NYSE:NVS).
Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idec's Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis
Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis
Symptom overlap in anxiety and multiple sclerosis
Cerebral white matter blood flow and energy metabolism in multiple sclerosis
Our results suggest that in MS patients there is no relationship between reduced CBF in NAWM and impaired axonal mitochondrial metabolism or astrocytic PCr metabolism.
Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation
Assessing interactions between HLA-DRB1*15 and infectious mononucleosis on the risk of multiple sclerosis
Perceived and actual arm performance in multiple sclerosis: relationship with clinical tests according to hand dominance
This study aimed to determine the relation between real-life arm performance and clinical tests in MS. Real-life arm performance is decreased in wheelchair-bound MS patients and can be best predicted by measures on ‘body functions & structures’ level and fine motor control.
Retinal nerve fiber layer thickness in benign multiple sclerosis
International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions
Pediatric onset multiple sclerosis: McDonald criteria 2010 and the contribution of spinal cord MRI
Application of the McDonald 2010 criteria for the diagnosis of multiple sclerosis in an Argentinean cohort of patients with clinically isolated syndromes
Childhood body mass index and multiple sclerosis risk: a long-term cohort study
Obesity in late adolescence has been associated with an increased risk of multiple sclerosis (MS); however, it is not known if body size in childhood is associated with MS risk. Having a high BMI in early life is a risk factor for MS, but the mechanisms underlying the association remain to be elucidated.
A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica)
Definite diagnosis of inflammatory demyelinating disease (multiple sclerosis (MS) and neuromyelitis optica (NMO)) may require time, but early treatment offers the opportunity to maximize patient outcomes.
Half of new MS patients may soon get Biogen’s Tecfidera Boston-based financial services group Cowen Group Inc. said Friday morning that based on patient data, Biogen Idec Inc.’s new drug, Tecfidera, may soon be getting more than half of all new multiple sclerosis patients. The Weston, Mass. biotech launched Tecfidera in March and has managed to outdo already-high expectations ever since. During its first three months on the market, the drug accounted for more than 10 percent of the Weston, Mass.-based drug company’s second-quarter revenues of $1.7 billion, which was up 21 percent year-over-year.
Cannabis was extensively used as a medicine throughout the developed world in the nineteenth century but went into decline early in the twentieth century ahead of its emergence as the most widely used illicit recreational drug later that century. This paper will then go on to review clinical research exploring the potential of cannabinoid medicines in the following indications: symptomatic relief in multiple sclerosis, chronic neuropathic pain, intractable nausea and vomiting, loss of appetite and weight in the context of cancer or AIDS, psychosis, epilepsy, addiction, and metabolic disorders.
Post-Tysabri (natalizumab) clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up.
There is an urgent need to identify the best strategies to prevent the loss of natalizumab (N) beneficial effects after its suspension. The objective is to evaluate the clinical and radiological disease activity and to test the efficacy of immunomodulatory/immunosuppressive drugs (IT) after N suspension.
Quality of life and employment in persons with multiple sclerosis.
Results of the study emphasize the need for the provision of quality vocational services to persons with MS. Issues such as quality vocational services, timeliness, and the importance of continued work are discussed.
The experience of being grounded: a phenomenological study of living with a wheelchair.
The purpose of this existential-phenomenological study was to investigate the experience of being in a wheelchair. It was a prelude to a pilot study examining the effect of "seated" Tai Chi. The accommodations from the ADA Act have greatly facilitated the independence for those who are disabled, yet many obstacles remain.
Epstein-Barr virus in oral shedding of children with multiple sclerosis
Notre Dame Men's Tennis Set To Host "Smash MS" Clinic Saturday
Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study
Tour de South Shore ride to benefit Alzheiemer's, MS research
Monoclonal antibodies in targeted therapy.
What sample sizes for reliability and validity studies in neurology?
Improved operator agreement and efficiency using the minimum area contour change method for delineation of hyperintense multiple sclerosis lesions on FLAIR MRI.
A Novel pH-Sensitive Interferon-β (INF-β) Oral Delivery System for Application in Multiple Sclerosis.
Neuromyelitis optica: atipic clinic presentation.
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development.
Connexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis optica.
Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?
Matrix metalloproteinases and their pathological upregulation in multiple sclerosis: an overview.
Meta-Analysis of the Correlation Between Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis.
To determine whether a correlation exists between chronic cerebrospinal venous insufficiency (CCSVI) and multiple sclerosis (MS).
Dry Eyes Tied to Lower Pain Threshold
Cognitive functions in multiple sclerosis: impact of gray matter integrity.
Our aim was to investigate the impact of gray matter (GM) integrity on cognitive performance in multiple sclerosis (MS), and its relationship with white matter (WM) integrity and presence of lesions. GM and WM integrity of specific networks influences cognitive performance in MS. However, GM damage assessed by DTI only adds a small increment to the explained variance by WM in predicting cognitive functioning.
(CCVI) Chronic cerebrospinal venous insufficiency--pathophysiology and treament
Multiple sclerosis (sclerosis multiplex--SM) is a chronic nervous sytem disease, which through formation of demyenilisation focus in the central nervous system leads to deterioration of its various functions. In the consequence it may cause invalidity of patient.
Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis
Symptom overlap in anxiety and multiple sclerosis
Cerebral white matter blood flow and energy metabolism in multiple sclerosis
Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation
Assessing interactions between HLA-DRB1*15 and infectious mononucleosis on the risk of multiple sclerosis
Perceived and actual arm performance in multiple sclerosis: relationship with clinical tests according to hand dominance
Retinal nerve fiber layer thickness in benign multiple sclerosis
International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system
Pediatric onset multiple sclerosis: McDonald criteria 2010 and the contribution of spinal cord MRI
Application of the McDonald 2010 criteria for the diagnosis of multiple sclerosis in an Argentinean cohort of patients with clinically isolated syndromes
Childhood body mass index and multiple sclerosis risk: a long-term cohort study
High risk of cardiovascular diseases after diagnosis of multiple sclerosis
Brain Changes May Explain Stroke Risk In Migraine Sufferers
Some people who get migraines do have a slightly higher risk of stroke. And some of the brain changes identified in the study look like mini strokes. "On the MRI migraines look like very tiny strokes," Lipton tells Shots. But the people aren't having any stroke symptoms. Still, Lipton is convinced that the process is the same. "We now know it's a risk factor for these very small silent strokes,"
Migraine and structural changes in the brain: A systematic review and meta-analysis
Migraine prevalence, socioeconomic status, and social causation
Sunbathing more effective than vitamin D in preventing multiple sclerosis
A
little ray of sunshine can help combat fatigue and depression and
decrease the risk of multiple sclerosis, according to new findings.
GETTING a regular dose of sunshine is much more effective than vitamin D
at combating fatigue and depression. STUDY: Participants also reported
on the length of time they spent sunbathing. It emerged that those who
spent longer in the sun suffered less from fatigue and depression. MS study targets damage affecting nerves
Dr Veronique Miron, MRC for Regenerative Medicine at the University of Edinburgh, explains that "In multiple sclerosis patients, the protective layer surrounding ..
A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica)
2010 McDonald criteria in a pediatric cohort: is positivity at onset associated with a more aggressive multiple sclerosis course?
A case of hereditary diffuse leukoencephalopathy with axonal spheroids caused by a de novo mutation in CSF1R masquerading as primary progressive multiple sclerosis
Gene expression changes underlying cortical pathology: clues to understanding neurological disability in multiple sclerosis
Higher Relative Risk for Multiple Sclerosis in a Pediatric and Adolescent Diabetes Population: Analysis From DPV Data Base
Indian Ranch to Host Concert To Benefit CFMS Foundation
Assessment of the influence of rehabilitation in patients treated in a hospital rehabilitation ward due to consequences of neurological diseases
Epidemiology in multiple sclerosis: a pilgrim's progress.
 |
| Dr. Jill Conway |
Charlotte doctor commits her career to treating multiple sclerosis
Dr. Jill Conway, director of the Multiple Sclerosis Cenjter at Carolinas Medical Center, enjoys working in a field with so many medical advances and one that ...
Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: study protocol for an exploratory randomized double- blind placebo-controlled trial.
European Commission Approves Genzyme's Once-Daily, Oral Aubagio...
Wall Street Journal
Review series on immune responses in neurodegenerative diseases: Oligodendrocyte-microglia cross-talk in the CNS.
Predictors of executive complaints and executive deficits in multiple sclerosis.
Among the study variables, depression was the strongest predictor of executive complaints. A high degree of neurological disability was the strongest predictor for executive deficit, measured by neuropsychological tests.
A comparison of sagittal short T1 inversion recovery and T2-weighted FSE sequences for detection of multiple sclerosis spinal cord lesions.
Multiple sclerosis (MS) is the most common disabling CNS disease of young adults. Short T1 inversion recovery sequence imaging not only significantly improves detection of MS lesions within the spinal cord, but also provides better contrast and conspicuity of visible lesions, creating a more confident diagnostic measure of MS extent and progression. Short T1 inversion recovery sequences of the spinal cord should be routinely obtained during initial and routine follow-up of MS.
Changes in expression of the antioxidant enzyme SOD3 occur upon differentiation of human bone marrow-derived mesenchymal stem cells in vitro.
A standardized motor imagery introduction program (MIIP) for neuro-rehabilitation: development and evaluation.
The quality of primary health care for chronically ill patients: a cross-sectional study.
The areas that the participants gave the highest ratings to are subjective and objective examinations, kindness and willingness to help. The strongest correlations between high assessments of the quality of care provided for chronically ill patients at primary care clinics were observed in the following variables: gender, age, level of education, frequency of visits, therapy conducted by a doctor at a specialist clinic, arterial hypertension, COPD and/or myocardial infarction.
Pathophysiology of the brain extracellular matrix: a new target for remyelination.
IL7RA haplotype-associated alterations in cellular immune function and gene expression patterns in multiple sclerosis.
Endogenous retroviruses and multiple sclerosis--new pieces to the puzzle.
Assessment of the influence of rehabilitation in patients treated in a hospital rehabilitation ward due to consequences of neurological diseases.
Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications.
Survival and predictors of mortality in systemic sclerosis associated pulmonary arterial hypertension: Outcomes from the PHAROS registry.
Obama administration will not block state marijuana laws, if distribution is regulated - The Washington Post
he Obama administration said Thursday that it would not challenge laws legalizing marijuana in Colorado and Washington State as long as those states maintain strict rules involving the sale and distribution of the drug.
In a memo to US Attorneys in all 50 States, Deputy Attorney General James M. Cole said the Justice Department is “committed to using its limited investigative and prosecutorial resources to address the most significant threats in the most effective, consistent and rational way.” He stressed that marijuana remains illegal under federal law.
The effect
of Prozac (fluoxetine) on progression in progressive multiple sclerosis:
a double-blind, randomized, placebo-controlled trial.ISRN Neurol. 2013 Jul 29;2013:370943. doi: 10.1155/2013/370943.
Department of Neurology, University Medical Center Groningen, University of Groningen, Postbus 30.001, 9700 RB Groningen, The Netherlands ; Department of Neurology, Rijnstate Hospital, Postbus 9555, 6800 TA Arnhem, The Netherlands.
Medication withdrawal may be an option for a select group of patients in relapsing-remitting multiple sclerosis.
This article describes the clinical and radiological evolution of a stable group of patients with relapsing-remitting multiple sclerosis that had their disease-modifying therapy (DMT) withdrawn. Withdrawal, however, should not be viewed as simply the suspension of treatment because these patients should be evaluated periodically, and the immunomodulators should be readily reintroduced if new attacks occur. Nonetheless, medication withdrawal is an option for a select group of patients.
Antiparasitic antibodies occur with similar frequency in patients with clinically established multiple sclerosis with or without oligoclonal bands in the cerebrospinal fluid.
Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis.
Department of Neurology, University of California, San Francisco, CA, USA.
Clinically isolated syndrome (CIS) is a central nervous system demyelinating event isolated in time that is compatible with the possible future development of multiple sclerosis (MS). Early risk stratification for conversion to MS helps with treatment decisions. Magnetic resonance imaging (MRI) is currently the most useful tool to evaluate risk.
Walking execution is not affected by divided attention in patients with multiple sclerosis with no disability, but there is a motor planning impairment.
Conclusion: MS patients with no disability did not show any influence of divided attention on walking execution. However, motor planning was overestimated as compared with real walking.
MicroRNAs as Novel Regulators of Neuroinflammation.
The effect of vitamin a supplementation on biochemical parameters in multiple sclerosis patients.
A&W's Cruisin' for a Cause Raises $5 Million Over 5 Years
Wall Street Journal: Cruisin' for a Cause (or le Rendez-vous A&W pour stopper la SP as it is known in Quebec) raised both funds and awareness of multiple sclerosis through a ...
In systemic sclerosis, anxiety and depression assessed by hospital anxiety depression scale are independently associated with disability and psychological factors.
Biomed Res Int. 2013;2013:507493. doi: 10.1155/2013/507493. Epub 2013 Jul 29.
Therapeutic Effect of Transplanted Human Wharton's Jelly Stem Cell-Derived Oligodendrocyte Progenitor Cells (hWJ-MSC-derived OPCs) in an Animal Model of Multiple Sclerosis.
Now this will Mekk you feel better!
The Samson Centre is the home of The Multiple Sclerosis Therapy Group in Guildford and is a small self-funded charity that provides physiotherapy and oxygen ...
Coping with a New Multiple Sclerosis Diagnosis
Huffington Post Canada: In her weekly column, Natalie answers your questions about caring for a family member or friend who needs extra support -- and caring for yourself as a ...
Band performs for MS
The Band of Her Majesty's Royal Marines Plymouth will perform a one-off fundraising concert for Multiple Sclerosis Auckland in September.
There is much to be learnt about the costs of multiple sclerosis in Latin America.
Multiple sclerosis is primarily a neurodegenerative disease.
Dr. Bill Code, M.D. to Present on Integrative Therapies for Brain Recovery in Multiple Sclerosis
Nutra Pharma Announces Delivery of Nyloxin(tm) to New Vitality
... biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and ...
FDA Warns of PML Case With Gilenya
MedPage Today: A patient being treated for multiple sclerosis and who had no history of using natalizumab (Tysabri) developed progressive multifocal ...
Home-based exercise program and fall-risk reduction in older adults with multiple sclerosis: phase 1 randomized controlled trial.
Sex-specific extent and severity of white matter damage in multiple sclerosis: Implications for cognitive decline.
Tecfidera’s Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches
Over the next six months, Tecfidera's patient share among DMT-treated RR-MS patients is anticipated to increase significantly to 16 percent. In fact, despite being the third oral DMT to reach the MS market, patient share for Tecfidera exceeds that for the first two oral DMTs for MS—Sanofi/Genzyme’s Aubagio (1 percent) and Novartis’s Gilenya (1 percent)—at the same stage of their respective launches. Current physician trial rate for Tecfidera (65 percent) beats that for Aubagio (33 percent) and Gilenya (53 percent).
Salt-Heavy Diets Can Lead to Autoimmune Diseases
Men's Journal
These ailments, which include multiple sclerosis, type 1 diabetes, inflammatory bowel disease, and psoriasis, result from an immune system gone haywire that ...
Prescription-Drug Coupons — No Such Thing as a Free Lunch
Visit
nearly any official website for a brand-name drug available in the
United States and, mixed in with links to prescribing and safety
information, you'll find links to drug “coupons,” including
copayment-assistance programs and monthly savings cards. Most offers are
variations on “Why pay more? With the [drug] savings card, you can get
[drug] for only $18 per prescription if eligible” or “Get a free
30-capsule trial of [drug] with your doctor's prescription and ask your
doctor if [drug] is right for you.” Why do manufacturers offer drug
coupons? Are they good for patients in the long run? Are they even
legal?Endogenous retroviruses and multiple sclerosis--new pieces to the puzzle
7thSpace Interactive (press release)
The possibility that retroviruses play a role in multiple sclerosis (MS) has long been considered; accumulating findings suggest this to be most likely in the form of ...
How Will the Obamacare Out-of-Pocket Cap Delay Affect MS Patients?
Healthline
For people with multiple sclerosis (MS) who must often pay high co-payments for health services and prescription drugs, this news comes as a crushing blow.
Opexa Therapeutics Inc awarded 50th patent for T-cell immunotherapy platform for multiple sclerosis
MENAFN.COM
Aug 28, 2013 (Menafn - M2 EQUITYBITES via COMTEX) --Biotechnology company Opexa Therapeutics Inc (nasdaqcm:OPXA) reported on Tuesday the receipt ...
Atos Tests Branded 'Farcical' After Finding Multiple Sclerosis ...
Huffington Post UK
The study looked at people with cystic fibrosis, multiple sclerosis, Parkinson's or rheumatoid arthritis who applied for Employment Support Allowance between ...
Big Sunfest cheques thrill MS societies
Canada.com
Both the Cowichan Exhibition Society and the Cowichan Valley chapter of the Multiple Sclerosis Society were the happy recipients of big cheques Thursday, ..
Non-myeloablative autologous haematopoietic stem cell transplantation
expands regulatory cells and depletes IL-17 producing mucosal-associated
invariant T cells in multiple sclerosis
Magnetic resonance monitoring of lesion evolution in multiple sclerosis
Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner
Community: Sept. 21 event to benefit MS program
Corvallis Gazette Times
The runs will benefit Oregon State's Multiple Sclerosis Exercise Program, which helps people with multiple sclerosis. Participants in the program receive free ...
Neurostimulators for the Treatment of Primary Headaches
Response rates reported in neurostimulation studies do not seem superior to those of the most effective prophylactic medications. Selection criteria for neurostimulation in headache patients are not uniform, and with few exceptions follow-up is too short to provide firm conclusions on long-term efficacy and safety, as well as costs. Notwithstanding these limitations, occipital nerve stimulation does seem to produce satisfactory improvement in chronic drug-resistant cluster headache and when it does not produce benefit, hypothalamic stimulation can be considered. Occipital nerve stimulation has been extensively investigated as a treatment of chronic migraine, but there is still some skepticism about its efficacy.[88]
Signs and symptoms of Multiple Sclerosis
Palm Beach Post
It is estimated that more than 2.1 million people worldwide are affected by multiple sclerosis (MS). Multiple sclerosis is a chronic, often disabling disease that ...
Atos Tests Branded 'Farcical' After Finding Multiple Sclerosis ...
Huffington Post UK
People with crippling illnesses like cystic fibrosis and multiple sclerosis are being found fit for ... The study looked at people with multiple sclerosis, Parkinson's or ...
Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner
Celia Oreja-Guevara, Heinz Wiendl, Bernd C. Kieseier, and Laura Airas
Therapeutic Advances in Neurological Disorders. published 27 August
2013, 10.1177/1756285613501575
http://tan.sagepub.com/cgi/content/abstract/1756285613501575v1?ct=ct
Natural killer cells and their receptors in multiple sclerosis
Gurman Kaur, John Trowsdale, and Lars Fugger
Brain. 2013; 136(9): p. 2657-2676
http://brain.oxfordjournals.org/cgi/content/abstract/136/9/2657?ct=ct
T-cell homeostasis in pediatric multiple sclerosis: Old cells in young patients
Bettina Balint, Jurgen Haas, Alexander Schwarz, Sven Jarius, Alexandra
Furwentsches, Kathrin Engelhardt, Cornelia Bussmann, Friedrich Ebinger,
Benedikt Fritzsching, Friedemann Paul, Ulrich Seidel, Stefan Vlaho,
Peter Huppke, Jutta Gartner, and Brigitte Wildemann
Neurology. 2013; 81(9): p. 784-792
http://www.neurology.org/cgi/content/abstract/81/9/784?ct=ct
Epidemiology in multiple sclerosis: a pilgrim's progress
John F. Kurtzke
Brain. 2013; 136(9): p. 2904-2917
http://brain.oxfordjournals.org/cgi/content/abstract/136/9/2904?ct=ct
Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis
Sofia V. Abrahamsson, Daniela F. Angelini, Amy N. Dubinsky, Esther
Morel, Unsong Oh, Joanne L. Jones, Daniele Carassiti, Richard Reynolds,
Marco Salvetti, Peter A. Calabresi, Alasdair J. Coles, Luca Battistini,
Roland Martin, Richard K. Burt, and Paolo A. Muraro
Brain. 2013; 136(9): p. 2888-2903
http://brain.oxfordjournals.org/cgi/content/abstract/136/9/2888?ct=ct
Magnetic resonance monitoring of lesion evolution in multiple sclerosis
Alex Rovira, Cristina Auger, and Juli Alonso
Therapeutic Advances in Neurological Disorders. 2013; 6(5): p. 298-310
http://tan.sagepub.com/cgi/content/abstract/6/5/298?ct=ct
The Multiple Sclerosis Association of America Launches New ...
Sacramento Bee
CHERRY HILL, N.J., Aug. 27, 2013 -- /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) is pleased to announce new website additions ...
Dresher Jeweler Holding Multiple Sclerosis Fundraiser
Patch.com
28, Lester Martin Jewelers, at 1650 Limekiln Pike in Dresher, will donate a portion of their proceeds to the Multiple Sclerosis Society of Greater Philadelphia.
Sobell changing gears on fundraiser
Lompoc Record
All money raised will be donated to the National Multiple Sclerosis Society. Registration fee is $50 and includes the run/ride, rest stops, support and gear and the ...
Use of a biomarker in exposure-response analysis to support dose selection for fingolimod.
Patient-related factors may affect the outcome of neuropsychological rehabilitation in multiple sclerosis.
Patient-related factors affected rehabilitation outcome, whereas illness- and intervention-related factors did not. The results showed that especially MS patients with male gender and more severe attentional deficits benefitted from the intervention (attention retraining, teaching compensatory strategies, psychoeducation, psychological support, and homework assignments).
Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy.
Prolonged and symptomatic bradycardia following a single dose of GILENYA
CLINICAL TRIAL: Investigators Recruiting For Study of Lower Dose of Gilenya Versus Copaxone In MS
Information on Current and Completed Pregnancy Registries for MS Therapies
(VIDEO) A Summer Spent At MS Center Offers Insight Into Mom's Battle
T-cell homeostasis in pediatric multiple sclerosis: Old cells in young patients
Premature immune senescence in children with MS: Too young to go steady
Glatiramer acetate–induced acute hepatotoxicity in an adolescent with MS
Cerebrospinal fluid derived immunoglobulin G of different multiple sclerosis patients share mutated sequences in complementarity determining regions.
The impact of diagnostic criteria for neuromyelitis optica in patients with MS: a 10-year follow-up of the South Atlantic Project.
Application and a proposed modification of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Canadian cohort of patients with clinically isolated syndromes.
Paroxysmal ataxia and dysarthria in multiple sclerosis.
Evidence against the Involvement of Chronic Cerebrospinal Venous Abnormalities in Multiple Sclerosis. A Case-Control Study.
Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials.
Genetic variation near IRF8 is associated with serologic and cytokine profiles in systemic lupus erythematosus and multiple sclerosis.
Health plan utilization and costs of specialty drugs within Multiple Sclerosis
Depression: Can a Coach Help?Adding old-fashioned technology -- the telephone -- to a Web-based intervention for depression improved adherence to the intervention, but there was no symptom benefit. Compared with those who did not receive telephone coaching to help navigate the depression treatment software, coached patients had significantly more login days (P=0.01) and were likely to continue to use the software for longer periods according to David Mohr, PhD, of Northwestern University Feinberg School of Medicine in Chicago, Ill.,
Pilates for people with multiple sclerosis who use a wheelchair: feasibility, efficacy and participant experiences.
Pilates appears to be efficacious in improving sitting stability and posture and decreasing pain and was also well tolerated by wheelchair users with MS. Further mixed methods studies are warranted. Implications for Rehabilitation Group-based core stability exercise or Pilates for people with MS who use wheelchair is a feasible and safe way of exercising for this patient group. Pilates exercises for people moderately to severely affected by MS resulted in a decrease in back and shoulder pain and improvement in sitting balance. Future appropriately powered randomised controlled studies into Pilates for people with MS reliant on wheelchair are warranted.
AUBAGIO (Teriflunomide) in relapsing multiple sclerosis: therapeutic utility
Therapeutic Advances in Chronic Dis
Surgery and Risk for Multiple Sclerosis: A Systematic Review and Meta-analysis of Case-Control Studies
Abstract-Background: Although the precise etiology of multiple sclerosis is largely unknown, there is some speculation that a prior history of surgery may be associated with the subsequent risk for developing the disease. Therefore, we aimed to examine surgery as a risk factor for the diagnosis of multiple sclerosis.
ease. 2013
The effects of pilates on balance, mobility and strength in patients with multiple sclerosis. NeuroRehabilitation. 2013 [Epub ahead of print]
Seizure Disorders Enter Medical Marijuana Debate
Evaluation of plaque detection and optimum time of enhancement in acute attack multiple sclerosis after contrast injection
Parasite Infections in Multiple Sclerosis Modulate Immune Responses through a Retinoic Acid-Dependent Pathway
Clinic speak: an holistic approach to MS version 3.1
Concomitant amyotrophic lateral sclerosis and paraclinical laboratory features of multiple sclerosis: coincidence or causal relationship?
Relapsing-remitting multiple sclerosis and chronic idiopathic neutropenia: a challenging combination
High dose thiamine improves fatigue in multiple sclerosis
The majority of the patients with multiple sclerosis (MS) experience
fatigue. Some observations indicate that fatigue and related
manifestations concomitant with MS could be associated with an
intracellular mild thiamine deficiency. Although blood thiamine and
thiamine pyrophosphate levels were within normal limit in all the
patients, high-dose thiamine therapy administered orally or parenterally
led to an appreciable improvement of the fatigue.The administration of large quantities of thiamine was effective in
reversing the fatigue in MS, suggesting that the abnormalities in
thiamine-dependent processes could be overcome by diffusion-mediated
transport at supranormal thiamine concentrations.The Physiological Changes of MS Multiple sclerosis attacks the body’s central nervous system and can cause quite severe reactions and symptoms if not properly treated. Here are a few physiological changes of multiple sclerosis (MS) and the effect that they have on your body. Some of the most well-known symptoms of MS can include muscle weakness, vision trouble, coordination problems, memory issues and sensations of numbness. However, you might not realize just how this condition affects the body. It affects the brain and nervous system and each patient’s symptoms can be less or more severe than the next, depending on their individual condition.
A new study appearing in the latest issue of STEM CELLS Translational Medicine is the first to demonstrate that, in fact, adipose-derived stem cells donated by older people are less effective than cells from their younger counterparts.
Biogen Idec, Elan facing suits over Tysabri side effects-Allegedly failed to warn of risks
On
Aug. 28 of last year Kimberley Yout, 45, was diagnosed with a rare
brain infection that developed as a side effect of Tysabri, a drug she
took for six years to keep her MS in check. Yout’s speech became
slurred, her gait unsteady, and her future uncertain. Now, she is suing
the two companies that marketed Tysabri — Biogen Idec Inc. of Weston and
the Irish drug maker Elan Pharmaceuticals Inc. The lawsuit is one of at least a half-dozen pending in Massachusetts and federal courts in three other states. In each case, plaintiffs are seeking more than $1 million in punitive damages from Biogen Idec and Elan on behalf of patients or their families. After taking Tysabri, the patients developed progressive multifocal leukoencephalopathy, known as PML, an infection of the brain’s white matter that can cause death or severe disability. Her complaint, filed Friday, alleges they failed to adequately warn patients of the risks some face from prolonged use of Tysabri.more
Shelley Peterman Schwarz: Secrets of a positive attitude!
Sylvi MacCormac credits her diagnosis with multiple sclerosis in 1982 at the age of 21 for her decision to create music full-time.
Dispelling the misconceptions about multiple sclerosis
Cognitive functions in multiple sclerosis: impact of gray matter integrity
Evaluation of circulating osteopontin levels in an unselected cohort of
Increased remissions in multiple sclerosis (MS) during late pregnancy may result from high levels of sex steroids such as estrogen and estriol. Estrogen (E2=17β-estradiol) protects against experimental autoimmune encephalomyelitis (EAE), but the cellular basis for E2-induced protection remains unclear.
Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).
Three men are raising money for the Multiple Sclerosis Society by attempting to walk the length of Hadrian's Wall.
The Bike MS: FedEx Rock-n-Roll Ride 2013 bike ride is in its fourth year in DeSoto County. The ride to end Multiple Sclerosis will be leaving the Landers Center ...
Chesapeake Challenge Walk raises money for MS research
Katy's muddy run for MS: Katy Hackling is gearing up to battle through thick mud, swim through lakes and run across challenging woodland to raise money for the Multiple Sclerosis Society.
Screening Mammo: Earlier is Better in Younger Women
More than two-thirds of breast cancer deaths occurred in younger women
with no history of mammography or with intervals of 2 years or more
between mammograms, a study of 7,300 breast cancer patients showed. More
than two-thirds of breast cancer deaths occurred in younger women with
no history of mammography or with intervals of 2 years or more between
mammograms. The findings support initiation of mammographic screening before age 50.
Migraine prevalence, socioeconomic status, and social causation
To determine whether the known higher prevalence of migraine in lower household (HH) income groups is explained by a higher
incidence rate or a lower remission rate.
The higher incidence of migraine in lower HH income groups is compatible
with the social causation hypothesis. Once initiated,
migraine remission is independent of HH income.
Onset and remission may have etiologically distinct causes.
Migraine and the social selection vs causation hypotheses
Choosing Wisely is an initiative of
the American Board of Internal Medicine Foundation in partnership with
Consumer Reports
and other consumer-oriented organizations to
encourage “physicians, patients and other health care stakeholders to
think and
talk about medical tests and procedures that may
be unnecessary, and in some instances cause harm.”1 The initiative's broader goal is to ensure that the right care is delivered at the right time and in the right place
Saskatchewan says multiple sclerosis liberation therapy clinical trial cancelled
For decades, the question of social selection vs social causation has been raised by public health researchers and social
scientists to explain the association between socioeconomic factors and mood disorders.
In 1960, Donald Acheson1 made the seminal observation that the global distribution of multiple sclerosis (MS) may be related to available hours of
sunshine; this observation was met with disbelief at the time.
To
determine whether brain atrophy and lesion volumes predict subsequent
10 year clinical evolution in multiple sclerosis
(MS). This large multicentre study
points to the complementary predictive value of atrophy and lesion
volumes for predicting long
term disability in MS.
Attributions and self-efficacy for physical activity in multiple sclerosis.
Self-efficacy is an important predictor of health-related physical activity in multiple sclerosis (MS). While past experiences are believed to influence efficacy beliefs, the explanations individuals provide for these experiences also may be critical.
Second line use of Fingolimod is as effective as (Tysabri) Natalizumab in a German out-patient RRMS-cohort.
Although Fingolimod is registered as a second-line drug in relapsing-remittend multiple sclerosis (RRMS) in Europe there are no clinical studies available comparing Fingolimod (FTY) and Natalizumab (N).
Which is the goal of cognitive rehabilitation in multiple sclerosis: the improvement of cognitive performance or the perception of cognitive deficits?
Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis
Protein array-based profiling of CSF identifies RBPJ as an autoantigen in
multiple sclerosis
Hunting for autoantibodies in multiple sclerosis
Neuroborreliosis during natalizumab treatment in multiple sclerosis
Multiple Sclerosis Appears to Originate in Different Part of Brain ...
Does robot-assisted gait training ameliorate gait abnormalities in multiple sclerosis? A pilot randomized-control trial.
Interactions of environment and genes in multiple sclerosis.
Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis
To determine whether the known higher prevalence of migraine in lower household (HH) income groups is explained by a higher
incidence rate or a lower remission rate.
The higher incidence of migraine in lower HH income groups is compatible
with the social causation hypothesis.
Severe Disability in Patients with Relapsing-Remitting Multiple Sclerosis Is Associated with Profound Changes in the Regulation of Leptin Secretion..
Randomized controlled trial of a behavioral intervention targeting symptoms and physical activity in multiple sclerosis.
The impact of sexual dysfunction on health-related quality of life in people with multiple sclerosis
Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II)
Increased remissions in multiple sclerosis (MS) during late pregnancy may result from high levels of sex steroids such as estrogen and estriol.
Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
To investigate whether early binding antibody (BAb) titers or different IFN-b biomarkers predict NAb evolution. BAb titers reliably predict NAbs. CXCL-10 is a promising sensitive biomarker for IFN-b response and its abrogation by anti-IFN-b antibodies.
Influence of multiple sclerosis, age and degree of disability, in the position of the contrast sensitivity curve peak.
A polymorphism in the resistin gene promoter and the risk of multiple sclerosis.
The Evaluation of the Retinal Nerve Fiber Layer in Multiple Sclerosis with Special-Domain Optical Coherence Tomography.
Y-39983, a Selective Rho-Kinase Inhibitor, Attenuates Experimental Autoimmune Encephalomyelitis via Inhibition of Demyelination.
Nuclear factor kappa B (NF-κB) in multiple sclerosis pathology.
Discovery of peptoid ligands for anti-aquaporin 4 antibodies.
Cytomegalovirus seropositivity is negatively associated with multiple sclerosis
Randomized controlled trial of a behavioral intervention targeting symptoms and physical activity in multiple sclerosis.
Randomized controlled trial of a behavioral intervention targeting symptoms and physical activity in multiple sclerosis.
Cigarette smoking and associated risk of multiple sclerosisExposure to cigarette smoke is emerging as an environmental risk factor for multiple sclerosis (MS). We investigated the possible association between environmental tobacco smoke, its cumulative exposure, and MS risk.
Our results demonstrate that cigarette smoking is significantly associated with an increased risk for MS. The risk effects of smoking were more noticeable in male patients and at higher tobacco doses.
Quality of life and employment in persons with multiple sclerosis.
In the current study, in an effort to examine the effects of type of employment upon quality of life (QOL), employment was divided into three categories (full-time employment, part-time employment, and unemployment). Results of the study emphasize the need for the provision of quality vocational services to persons with MS. Issues such as quality vocational services, timeliness, and the importance of continued work are discussed.
The experience of being grounded: a phenomenological study of living with a wheelchair.
The purpose of this existential-phenomenological study was to investigate the experience of being in a wheelchair. It was a prelude to a pilot study examining the effect of "seated" Tai Chi. The accommodations from the ADA Act have greatly facilitated the independence for those who are disabled, yet many obstacles remain.
on.
Monoclonal Antibodies in Treatment of Multiple Sclerosis.
Post-Tysabri (natalizumab) clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up.
No Differences Observed among Multiple Clinical S1P1 Receptor Agonists (Functional Antagonists) in S1P1 Receptor Down-regulation and Degradation.
Matrix metalloproteinases and their pathological upregulation in multiple sclerosis: an overview.
Standing Data Disproves Biomechanical Mechanism for Balance-Based Torso-Weighting.
Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?
Evolution of longitudinally extensive transverse myelitis in an aquaporin-4 IgG-positive patient.
[Genetic impairments of Wnt signaling pathways in hereditary high bone mass syndrome and sclerostosis diseases].
Steroid-responsive hearing impairment in NMO-IgG/aquaporin-4-antibody-
Connexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis optica.
PRISM: A Novel Research Tool to Assess the Prevalence of Pseudobulbar Affect Symptoms across Neurological Conditions.
Higher Relative Risk for Multiple Sclerosis in a Pediatric and Adolescent Diabetes Population: Analysis From DPV Data Base.
Mesenchymal stromal-cell transplants induce oligodendrocyte progenitor migration and remyelination in a chronic demyelination model.
Giant pilomatricoma in a patient with tuberous sclerosis, both diagnosed in the adult life.
On the estimation and correction of bias in local atrophy estimations using example atrophy simulations
Distribution and expression of fibroblast-specific protein chemokine CCL21 and chemokine receptor CCR7 in renal allografts.
Increased plasma interleukin-32 expression in patients with neuromyelitis optica.
1. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
Oral laquinimod may reduce (at least in the initial phase of treatment) some of the more destructive pathological processes in RRMS patients.
2. 2nd International Symposium on Gait and Balance in Multiple Sclerosis: interventions for gait and balance in MS.
Department of Physical Medicine and Rehabilitation, Kennedy Krieger Institute, Johns Hopkins University School of Medicine , Baltimore, MD , USA .
3. Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration.
4. Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders.
5. Disease-association analysis of an inflammation-related feedback loop.
6. Electrodiagnostic evaluation of peripheral nervous system changes in patients with multiple sclerosis.
7. Prevalence of neurological disorders in Al Quseir, Egypt: methodological aspects.
8. Longitudinally extensive varicella-zoster virus myelitis in a multiple sclerosis patient.
9. Alpha-B-crystallin induces an immune-regulatory and antiviral microglial response in preactive multiple sclerosis lesions.
10. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) in humans with multiple sclerosis.
11. Muscle-specific kinase antibody positive myaesthenia gravis and multiple sclerosis co-presentation: A case report and literature review.
12. A patient's perspective of partnership in the treatment of multiple sclerosis: MS regimes-An orchestrated approach.
13. Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration.
14. 2nd International Symposium on Gait and Balance in Multiple Sclerosis: interventions for gait and balance in MS.
15. Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders.
16. Autoantibodies to Potassium Channel KIR4.1 in Multiple Sclerosis.
17. Pediatric Inflammatory Diseases. Part IV: Miscellaneous, Reye, PRES, Sarcoidosis.
18. Pediatric inflammatory diseases. Part I: multiple sclerosis.
19. Practical Aspects of Shortening Acquisition Time in Brain MR Susceptibility-Weighted Imaging.
20. β-Arrestins 1 and 2 are critical regulators of inflammation.
21. BIOGEN HAS 3 NEW MS TREATMENTS THEY ARE WORKING ON THAT ARE BEING PRESENTED AT THE WORLDWIDE MEETING OF NEUROLOGISTS: ECTRIMS
22. VIDEO GAME HELPS EASE SYMPTOMS OF MS! PLUS: MSers CAN ENROLL IN UNIVERSITY'S STUDY
READ 109 MORE STUDIES & STORIES BY CLICKING ON "Read More" BELOW:
23. "First Direct Measurement of Spinal Cord Myelin in Multiple Sclerosis"
24. MS News Channel Expert Neurologist: Brian R. Apatoff, MD, PhD: MULTIPLE SCLEROSIS AND PAIN
businesswire.com
26. Dancing With the Stars 2013’s Jack Osbourne Will “Persevere” After Wife Lisa Stelly’s Miscarriage
wetpaint.com
We suggest that our virtual reality program enables anticipatory PC and response mechanisms and might serve as a successful therapeutic alternative in situations in which conventional therapy is not readily available.
lep.co.uk
health.com
hellomagazine.com
31. Carboxypeptidase N-deficient mice present with polymorphic disease phenotypes on induction of experimental autoimmune encephalomyelitis.
Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.:
32. Structure-Kinetics Relationships - an overlooked parameter in hit-to-lead optimization: a case of cyclopentylamines as CCR2 antagonists.
33. Parental illness, attachment dimensions, and health beliefs: testing the cognitive-behavioural and interpersonal models of health anxiety.
huffingtonpost.com
prnewswire.com
sciencebusiness.net
dailyecho.co.uk
sciencedaily.com
cbc.ca
dailyrecord.com
41. Multiple sclerosis on the rise in region
dailystar.com
thestar.com
pharmafile.com
44. THE SCIENCE OF TRIPS & FALLS IS IMPORTANT READING FOR ALL MS'ers
45. Dad pleads for trial drug to slow progressive illnessDAD PLEADS FOR DRUG TRIAL TO SLOW HIS PRIGRESSIVE MS!
46. Adam Possner, MD: THE EPLEY MANEUVER....THE CLOSEST DOCTORS COME TO EXORCISM
47. SLIDESHOW: "17 Multiple Sclerosis Treatments"
48. Genzyme’s second MS drug in a month approved in Europe! With Lemtrada's EU nod, Sanofi preps for dual MS drug launches
Sanofi now has not one, but two big multiple sclerosis launches to get under way in Europe. Two weeks after nabbing EU approval for its new MS pill Aubagio, Sanofi got regulatory clearance for Lemtrada
49. Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth
prnewswire.com 50. Biogen: All Reasons For Bulls To Be Happy
seekingalpha.com
44. THE SCIENCE OF TRIPS & FALLS IS IMPORTANT READING FOR ALL MS'ers
45. Dad pleads for trial drug to slow progressive illnessDAD PLEADS FOR DRUG TRIAL TO SLOW HIS PRIGRESSIVE MS!
46. Adam Possner, MD: THE EPLEY MANEUVER....THE CLOSEST DOCTORS COME TO EXORCISM
47. SLIDESHOW: "17 Multiple Sclerosis Treatments"
48. Genzyme’s second MS drug in a month approved in Europe! With Lemtrada's EU nod, Sanofi preps for dual MS drug launches
Sanofi now has not one, but two big multiple sclerosis launches to get under way in Europe. Two weeks after nabbing EU approval for its new MS pill Aubagio, Sanofi got regulatory clearance for Lemtrada
49. Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth
prnewswire.com 50. Biogen: All Reasons For Bulls To Be Happy
seekingalpha.com
pmlive.com
53. NYT: Patients fear drug cost spikes under health law
nbcnews.com
pharmafile.com
nbcnews.com
54. Teva Copy to Boost Billionaire-Backed Drugmaker: Corporate India
bloomberg.com
56. Report exposes failings in care of new MS patients
scottishconservatives.com
57. European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada™ (alemtuzumab)
thestreet.com
bloomberg.com
eveningtelegraph.co
scottishconservatives.com
57. European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada™ (alemtuzumab)
thestreet.com
58. "Sometimes I find myself thinking pretty negative thoughts about my multiple sclerosis and I notice that my symptoms are worse"
59. "What is MS? Could You Have MS? 16 Multiple Sclerosis Symptoms (SLIDESHOW)"
60. 4 ways to manage double vision: Solutions to help manage this common symptom of MS
61. Terri Spats, Columnist & News Editor: MY COLUMN TODAY IS A MESSAGE TO THOSE WITH NO INVISIBLE ILLNESS
62. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort
Multiple Sclerosis Journal. 2013; 19(11): p. 1533-1538
63. Teriflunomide for the treatment of multiple sclerosis.Oh J, O'Connor PW. Semin Neurol. 2013 Jul;33(3):307-8. doi: 10.1055/s-0033-1354604. Epub 2013 Sep 21.
64. Endurance training is feasible in severely disabled patients with progressive multiple sclerosis. Skjerbæk A, Næsby M, Lützen K, Møller A, Jensen E, Lamers I, Stenager E, Dalgas U.
Mult Scler. 2013 Sep 20.
65. The relationship of cognitive impairment with neurological and psychiatric variables in multiple sclerosis patients.Karadayi H, Arisoy O, Altunrende B, Boztas HM, Sercan M.
Int J Psychiatry Clin Pract. 2013 Sep 19. [Epub ahead of print]
66. Altered likelihood of brain activation in attention and working memory networks in patients with multiple sclerosis: An ALE meta-analysis. Kollndorfer K, Krajnik J, Woitek R, Freiherr J, Prayer D, Schöpf V. Neurosci Biobehav Rev. 2013 Sep 18.
67. Circulating dendritic cells of multiple sclerosis patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factors. Thewissen K, Nuyts AH, Deckx N, Wijmeersch BV, Nagels G, D'hooghe M, Willekens B, Cras P, Eijnde BO, Goossens H, Van Tendeloo VF, Stinissen P, Berneman ZN, Hellings N, Cools N. Mult Scler. 2013 Sep 20.
68. Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan. Rudick RA, Larocca N, Hudson LD; MSOAC. Mult Scler. 2013 Sep 20. [Epub ahead of print]
69. Outcomes after Microvascular Decompression for Patients with Trigeminal Neuralgia and Suspected Multiple Sclerosis.Ariai MS, Mallory GW, Pollock BE. World Neurosurg. 2013 Sep 19.
70. Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis - a systematic review. Wens I, Dalgas U, Stenager E, Eijnde BO.
Mult Scler. 2013 Sep 18. [Epub ahead of print]
71.Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database .Mackenzie IS, Morant SV, Bloomfield GA, Macdonald TM, O'Riordan J. J Neurol Neurosurg Psychiatry. 2013 Sep 19
72. Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients
Multiple Sclerosis Journal. 2013; 19(11): p. 1478-1484
73. What Is the JC Virus?
74. Royal recognition for Sussex Multiple Sclerosis Treatment Centre work
theargus.co
businesswire.com
southwalesargus.co
businesswire.com
sciencedaily.com
netdoctor.co
eurekalert.org
brightsurf.com
harrogateadvertiser.co
theolympian.com
bizjournals.com
85. "STING may take the bite out of autoimmune diseases"
86. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
In Assessment of OraL Laquinimod in PrEventing ProGRession in Multiple SclerOsis (ALLEGRO), a phase III study in relapsing-remitting multiple sclerosis (RRMS), oral laquinimod slowed disability and brain atrophy progression, suggesting laquinimod may reduce tissue damage in MS. MRI techniques sensitive to the most destructive aspects of the disease were used to further investigate laquinimod's potential effects on inflammation and neurodegeneration. Oral laquinimod may reduce (at least in the initial phase of treatment) some of the more destructive pathological processes in RRMS patients.
87. A 10-year follow-up of a population-based study of people with multiple sclerosis in Stockholm, Sweden: Changes in disability and the value of different factors in predicting disability and mortality.
The aims of this study were to evaluate changes in disability over ten years in PwMS, and to explore the value of personal and disease-specific factors and depressive symptoms in predicting disability. A further aim was to explore the value of these factors as predictors of mortality.This study illustrates the importance of tailored interventions for PwMS and highlights the need for health-care professionals to consider the psychological aspects of the disease. Furthermore, our results indicate that the Expanded Disability Status Scale was a useful tool for predicting future disability.
88. The B1-cell subpopulation is diminished in patients with relapsing-remitting multiple sclerosis.
89. Oxidative modification of serum proteins in multiple sclerosis.
90. Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).
Multiple Sclerosis Journal. 2013; 19(11): p. 1485-1492
Multiple Sclerosis Journal. 2013; 19(11): p. 1518-1525
Multiple Sclerosis Journal. 2013; 19(11): p. 1428-1436
96. "Why do some people experience aggressive worsening of their multiple sclerosis and others experience a mild course?"
ctvnews.ca
silive.com
kentucky.com
100. Girl Swims to to Reach Fundraising
montereyherald.com
cleveland.com
102. Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
bionity.com
businesswire.com
104. Swimming for a Cause: Scotts Valley youngster raises awareness, money for MS Association
insidebayarea.com
businesswire.com
theguardian.com
107. Manes & Motions: An Equine Assist For Special Needs courant.com
108. Trekking Hadrian’s Wall for Multiple Sclerosis Society
horncastlenews.co
edmunds.com
prnewswire.com
silive.com
113. Assessing risks of multiple sclerosis therapies.
Service of Neurology, Department of Clinical Neurosciences, University Hospital of Lausanne, CHUV BH-10, 46 rue du Bugnon, 1011 Lausanne, Switzerland.: J Neurol Sci. 2013 Sep 15;332(1-2):59-65. doi: 10.1016/j.jns.2013.06.013.
Service of Neurology, Department of Clinical Neurosciences, University Hospital of Lausanne, CHUV BH-10, 46 rue du Bugnon, 1011 Lausanne, Switzerland.: J Neurol Sci. 2013 Sep 15;332(1-2):59-65. doi: 10.1016/j.jns.2013.06.013.
Clemens
Warnke, Anne K. Mausberg, Mark Stettner, Thomas Dehmel, Lina, Nekrich,
Gerd Meyer zu Horste, Hans-Peter Hartung, Anna Fogdell-Hahn, Ortwin
Adams, and Bernd C. KieseierNeurology. published 18 September 2013,
10.1212/WNL.0b013e3182a84101
115. Psychological and physical predictors of illness intrusiveness in patients with multiple sclerosis.
Ferkauf Graduate School of Psychology, Yeshiva University, United States; Multiple Sclerosis Center of Holy Name Medical Center, United States.: Snyder S, Foley FW, Farrell E, Beier M, Zemon V.
J Neurol Sci. 2013 Sep 15;332(1-2):41-4. doi: 10.1016/j.jns.2013.06.009. Epub 2013 Jul 10.
116. Reduced grey matter perfusion without volume loss in early relapsing-remitting multiple sclerosis.
New Zealand Brain Research Institute, , Christchurch, New Zealand.: Debernard L, Melzer TR, Van Stockum S, Graham C, Wheeler-Kingshott CA, Dalrymple-Alford JC, Miller DH, Mason DF. J Neurol Neurosurg Psychiatry. 2013 Sep 13.
Grey matter (GM) pathology in multiple sclerosis (MS) is associated with progressive long-term disability. Detection of GM abnormalities in early MS may therefore be valuable in understanding and predicting the long-term course. However, structural MRI measures such as volume loss have shown only modest abnormalities in early relapsing-remitting MS (RRMS). We therefore investigated for evidence of abnormality in GM perfusion, consistent with metabolic dysfunction, in early RRMS.
The decrease in GM perfusion in the absence of volume loss is consistent with neuronal metabolic dysfunction in early RRMS. Future studies in larger cohorts and longitudinal follow-up are needed to investigate the functional and prognostic significance of the early GM perfusion deficits observed.
117. Bipolar disorder and multiple sclerosis: A case series.
Department of Neurology, Razi Hospital, Mannouba, Tunis, Tunisia.: Sidhom Y, Djebara MB, Hizem Y, Abdelkefi I, Kacem I, Gargouri A, Gouider R.
Behav Neurol. 2013 Sep 12. [Epub ahead of print]
118. Delayed Recovery of Leg Fatigue Symptoms Following a Maximal Exercise Session in People With Multiple Sclerosis.
1Oxford Brookes University, Oxford, UK.: Dawes H, Collett J, Meaney A, Duda J, Sackley C, Wade D, Barker K, Izadi H.
Neurorehabil Neural Repair. 2013 Sep 11.
Symptoms of fatigue were investigated during and following a single exercise session.
Monitoring leg fatigue symptoms during and through recovery from physical activities may help guide participation in physical activities for PwMS, particularly in people managing high levels of fatigue.
119. Exacerbation of experimental autoimmune encephalomyelitis by passive transfer of IgG antibodies from a multiple sclerosis patient responsive to immunoadsorption.
Neuroimmunology and Neuromuscular Disorders Unit, Foundation IRCCS Neurological Institute C. Besta, Via Celoria 11, 20133 Milan, Italy. Electronic address: rpedotti@istituto-besta.it.: Pedotti R, Musio S, Scabeni S, Farina C, Poliani PL, Colombo E, Costanza M, Berzi A, Castellucci F, Ciusani E, Confalonieri P, Hemmer B, Mantegazza R, Antozzi C.
J Neuroimmunol. 2013 Sep 15;262(1-2):19-26.
120. Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
Cladribine causes sustained reduction in peripheral T and B cell populations while sparing other immune cells. We determined two populations of dendritic cells (DCs): namely CD1c(+)/CD19(-) (myeloid DCs) and CD303(+)/CD123(+) (plasmacytoid DCs), CD19(+) B lymphocytes, CD3(+) T lymphocytes and CD4(+) or CD8(+) subpopulations in patients with multiple sclerosis after cladribine therapy.
We noticed significant trend to increase the CD303(+) circulating the dendritic cells. This population produces large amounts of IFN-alfa. We found significant and rapid decrease in B cells and CD4(+) Th cells. Our results suggest two possible ways of beneficial cladribine influence on immune system in MS. Induction of IFN-alfa producing cells and their predominance over BDCA-1(+) DCs, which are associated with cytotoxic response. Additionally, cladribine could influence two populations of lymphocytes: B cells and Th lymphocytes responsible for induction of immune response against myelin antigens.
121. Intrathecal oligoclonal IgG synthesis in multiple sclerosis.
Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands; UCL Institute of Neurology, Neuroimmunology & CSF Laboratory, Queen Square, London, United Kingdom. Electronic address: a.petzold@vumc.nl.: J Neuroimmunol. 2013 Sep 15;262(1-2):1-10
Inez Wens, Ulrik Dalgas, Egon Stenager, and Bert O. Eijnde
Multiple Sclerosis Journal. published 18 September 2013
123. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort
Tomas Olsson, Anat Achiron, Lars Alfredsson, Thomas Berger, David
Brassat, Andrew Chan, Giancarlo Comi, Mefkure Eraksoy, Harald Hegen,
Jan Hillert, Poul Erik Hyldgaard Jensen, Lucia Moiola, Kjell-Morten
Myhr, Annette Oturai, Sven Schippling, Aksel Siva, Per Soelberg
Sorensen, Anne-Kathrin Trampe, Thomas Weber, James Potts, Tatiana
Plavina, Dominic Paes, Meena Subramanyam, Heinz Wiendl, Hussein Dib,
Deniz Uren, Bernhard Hemmer, and Dorothea Buck
Multiple Sclerosis Journal. 2013; 19(11): p. 1533-1538
Brassat, Andrew Chan, Giancarlo Comi, Mefkure Eraksoy, Harald Hegen,
Jan Hillert, Poul Erik Hyldgaard Jensen, Lucia Moiola, Kjell-Morten
Myhr, Annette Oturai, Sven Schippling, Aksel Siva, Per Soelberg
Sorensen, Anne-Kathrin Trampe, Thomas Weber, James Potts, Tatiana
Plavina, Dominic Paes, Meena Subramanyam, Heinz Wiendl, Hussein Dib,
Deniz Uren, Bernhard Hemmer, and Dorothea Buck
Multiple Sclerosis Journal. 2013; 19(11): p. 1533-1538
124. Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients
Ralph HB Benedict, Hanneke E Hulst, Niels Bergsland, Menno M
Schoonheim, Michael G Dwyer, Bianca Weinstock-Guttman, Jeroen JG
Geurts, and Robert Zivadinov
Multiple Sclerosis Journal. 2013; 19(11): p. 1478-1484
125. Clinical characteristics and outcome of multiple sclerosis in Korea: does multiple sclerosis in
Korea really differ from that in the Caucasian populations?
Su-Hyun Kim, So-Young Huh, Woojun Kim, Min Su Park, Suk-Won Ahn,
Joong-Yang Cho, Byung Jo Kim, and Ho Jin Kim
Multiple Sclerosis Journal. 2013; 19(11): p. 1493-1498
Joong-Yang Cho, Byung Jo Kim, and Ho Jin Kim
Multiple Sclerosis Journal. 2013; 19(11): p. 1493-1498
Joseph R Berger, Jennifer Pocoski, Ronald Preblick, and Susan Boklage
Multiple Sclerosis Journal. 2013; 19(11): p. 1526-1532
Multiple Sclerosis Journal. 2013; 19(11): p. 1526-1532
J Frau, D Cossu, G Coghe, L Lorefice, G Fenu, M Melis, D Paccagnini, C
Sardu, MR Murru, S Tranquilli, MG Marrosu, LA Sechi, and E Cocco
Multiple Sclerosis Journal. 2013; 19(11): p. 1437-1442
Sardu, MR Murru, S Tranquilli, MG Marrosu, LA Sechi, and E Cocco
Multiple Sclerosis Journal. 2013; 19(11): p. 1437-1442
Nete M Nielsen, Peter Bager, Egon Stenager, Bo V Pedersen, Nils
Koch-Henriksen, Henrik Hjalgrim, and Morten Frisch
Multiple Sclerosis Journal. 2013; 19(11): p. 1473-1477
Koch-Henriksen, Henrik Hjalgrim, and Morten Frisch
Multiple Sclerosis Journal. 2013; 19(11): p. 1473-1477
Violaine K Harris, Nicola Donelan, Qi Jiang Yan, Kristi Clark, Amir
Touray, Mustapha Rammal, and Saud A Sadiq
Multiple Sclerosis Journal. 2013; 19(11): p. 1462-1472
Touray, Mustapha Rammal, and Saud A Sadiq
Multiple Sclerosis Journal. 2013; 19(11): p. 1462-1472
132. Place of death, and its relation with underlying cause of death, in Parkinson’s disease, motor neurone disease, and multiple sclerosis: A population-based study Little is known about place of death
Wall Street Journal
Over
1,900 Biogen Idec (NASDAQ: BIIB) employees will trade in their lab
coats and computers today to participate in the company's third annual
"Care Deeply Volunteer Day."For this
day of service, Biogen Idec employees are given a paid day off to
volunteer at a service project in their community. This year, employees
are estimated to serve over 9,500 volunteer hours in more than 28
countries in the communities where the company operates.
134. UCSF Researcher First Winner of Prize for Innovative Work on Multiple SclerosisUCSF News Services
Telemanagement
Little is known about place of death in chronic neurological diseases. Mortality statistics are ideal for examining trends in place of death, but analyses are limited by coding rule changes. Underlying cause of death has a marked effect on place of death. The effects of coding rule changes are an essential consideration for all research using underlying cause of death to study place of death.
The
role of the adaptive immune system and more specifically T cells in the
pathogenesis of multiple sclerosis (MS) has been studied extensively.
Emerging evidence suggests that dendritic cells (DCs), which are innate
immune cells, also contribute to MS. DCs in MS are in a pro-inflammatory
state, have a migratory phenotype and are affected by genetic risk
factors, thereby contributing to pathogenic responses.
Kuwait
was considered as low to intermediate risk area for MS. Kuwait is
considered a high-risk area for MS. The significant increase in
prevalence and incidence rates may represent a true increase despite the
improvement in case ascertainment and case definition.
The New York Times
142. Proud MS team celebrates success at abseil challengeShoreham Herald
143. Meet The IESE MBA With A Passion For Health CareBusinessBecause
Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Faculty of Health Sciences, ReyJuanCarlosUniversity, Alcorcón, Madrid, Spain.: Gutiérrez RO, Galán Del Río F, Cano de la Cuerda R, Alguacil Diego IM, González RA, Page JC.
To demonstrate the potential improvements in balance and PC among patients with MS who complete a virtual reality telerehabilitation program that represents a feasible alternative to physical therapy for situations in which conventional treatment is not available.
We suggest that our virtual reality program enables anticipatory PC and response mechanisms and might serve as a successful therapeutic alternative in situations in which conventional therapy is not readily available.
146. Carboxypeptidase N-deficient mice present with polymorphic disease phenotypes on induction of experimental autoimmune encephalomyelitis.
Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.: Hu X, Wetsel RA, Ramos TN, Mueller-Ortiz SL, Schoeb TR, Barnum SR.
JOSI CREEK, GUEST COLUMNIST: "They took my morphine cold turkey from me because i don't act normal they thought i was a drug abuser
Patti McArthur, Columnist: MY PAIN DOC FIRED ME & SENT ME BACK TO MY MS DOCTOR WHO GAVE ME SHOTOS OF BOTOX IN MY SKULL TO HELP THE MIGRAINES!
The American Academy of Neurology's Top Five Choosing Wisely recommendations
DeAnn Burgess, Lemtrada Editor: MY LEMTRADA DIARY: I saw my neuro today & he tested me! I actually had knee reflexes!!!!!!!!!!!!!
Meg Jones, Columnist: MY COLUMN THIS WEEK IS ABOUT PERSEVERANCE]" WILL GIVE YOU GOOD TEARS & HOPE FOR THE FUTURE!
Valorie Diamond, Columnist: PAIN...LIVE OR LET RULE
FRIENDS & FAMILY DON'T UNDERSTAND YOUR MS? SHARE THIS ARTICLE WITH THEM: IT WILL MAKE THEM UNDERSTAND: "The Physiological Changes of MS"
STRESS IS NOT MS'S FRIEND! 20 Scientifically-Backed Ways To De-Stress Right Now
EDUCATIONAL ACTIVITY FOR: neurologists, neurology nurses, pharmacists and other healthcare professionals involved in the treatment of patients with multiple sclerosis.
KATRINA ANN TAYLOR, COLUMNIST: I WON'T GIVE UP ON MYSELF AFTER MY HEART BREAK & LOSS
Beth Dean, News Editor & Columnist: I'M PROUD TO SAY I'M A COPAXONE GIRL
Multiple Sclerosis Appears to Originate in Different Part of Brain Than Long Believed
Biogen Idec, Elan facing suits over Tysabri PML side effects! Biogen allegedly failed to warn Multiple Sclerosis patients of risks
FOR DOCTORS ONLY: Charting Progress in MS Treatment: Initiating, Monitoring, and Switching Disease-Modifying Therapy
Kerry Galcik, Columnist, MSnewsChannel.com: THIS IS MY 1ST COLUMN! I look forward to writing as a new columnist! Sexual dysfunction has a much larger detrimental impact on mental health than severity of MS physical disability.
Yvonne Decelis, Columnist: MY TECFIDERA DIARY: MY MEMORY & PAIN PROBLEMS ARE DISAPPEARING
LAUREN PARROTT IS OUR NEWEST COLUMNIST! In 2005, at the age of 21, Lauren was an intern at Good Morning America & has over 100 videos on YouTube
GET YOUR FREE MAGAZINE NOW: The Rocky Mountain MS Center's Magazine is FREE for our readers! Click either of the 2 links below to read the Summer Issue of InforMS
PAIN Week 2013: Proposed Opioid Reduction Guideline Reduces Depression, Pain
PAIN Week 2013:FDA Restricts Long-term Opioid Use to Combat Abuse
PAIN Week 2013: Five-Step Plan Helps Patients Cope With Pain
CINDI HOPPER, COLUMNIST: One of the worst things we have to face having MS is those days when our balance is not quite right
The FDA ordered label changes for long-acting and extended-release opioids such as OxyContin, limiting approved use to severe pain that cannot be relieved with other treatments
Valorie Diamond, Columnist: MY COLUMN THIS WEEK INCLUDES A FEW TIPS THAT HELP ME DEAL WITH MS
LOTS OF MSers NEED HELP WITH COGNITION: VIDEO GAME TRAINING CAN BOOST COGNITION
April Barbosa, Columnist & Poet: MEDICAL MARIJUANA GAVE ME MY LIFE BACK BY HELPING ME BATTLE THE MS MONSTER
PAIN Week 2013: Proposed Opioid Reduction Guideline Reduces Depression, Pain
